Alternative Method to Determine Specific Activity of Lu-177 by HPLC

被引:12
|
作者
Breeman, Wouter A. P. [1 ]
de Zanger, Rory M. S. [1 ]
Chan, Ho Sze [1 ]
de Blois, Erik [1 ]
机构
[1] Erasmus MC, Dept Nucl Med, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands
关键词
Lu-177-DOTA-TATE; DOTA-peptides; HPLC; Lutetium-177; specific activity; titration;
D O I
10.2174/1874471008666150312162340
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177-DOTA-peptides requires Lu-177 with high specific activity (SA) and values >740 GBq Lu-177 per mg Lu to maximise the atom% of Lu-177 over total Lu. Vendors provide SA values which are based on activity and mass of the target, whereas due to "burn-up" of target, these SA values are not accurate. For a radiochemist the SA of Lu-177 is of interest prior to radiolabeling. An alternative method to determine SA was developed by HPLC, which includes a metal titration of a known amount of DOTA-peptide with a known amount of activity (Lu-177), and a unknown amount of metal (Lu177+nat). Based on an HPLC separation of radiometal-DOTA-peptide and DOTA-peptide, and the concordant ratio of these components the metal content (Lu177+nat) can be calculated, and eventually the SA of Lu-177 can be accurately determined. These experimentally determined SA values exceeded the estimated values provided by vendors by 27 +/- 16%, (range 6-73 %). The deviation of SA values for samples from the same Lu batch was <2% (n >= 10). In conclusion: the SA of Lu-177 is apparently often higher as stated by vendors in comparison to the experimentally determined actual values. For this reason, the SA of Lu-177-DOTA-TATE and other Lu-DOTA-peptides could be increased accordingly.
引用
收藏
页码:119 / 122
页数:4
相关论文
共 50 条
  • [21] Radiation Dosimetry Aspects of Lu-177
    Lassmann, Michael
    Eberlein, Uta
    CURRENT RADIOPHARMACEUTICALS, 2015, 8 (02) : 139 - 144
  • [22] Optimisation of Lu-177 therapy administration
    Fernandez, R.
    Rai, S.
    Perry, A.
    Johnson, J.
    Croasdale, P.
    Eftychiou, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S661 - S662
  • [23] Spectrum analysis and counting efficiency of Lu-177 with specific counting systems
    Younan, Jack
    Zimmer, Mike
    Riehle, Lisa
    Spies, Stewart
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [24] Serial Dosimetry in Peptide Receptor Radionuclide Therapy using Lu-177 DOTATATE or Lu-177 DOTATOC in the same Patient
    Schuchardt, C.
    Kulkarni, H.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S139 - S139
  • [25] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Josephine Graf
    Ulrich-Frank Pape
    Henning Jann
    Timm Denecke
    Ruza Arsenic
    Winfried Brenner
    Marianne Pavel
    Vikas Prasad
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 881 - 894
  • [26] Comparative evaluation of carrier added and non carrier added Lu-177 for preparation of therapeutic doses of Lu-177 radiopharmaceuticals
    Bhusari, P.
    Shukla, J.
    Singh, H.
    Sood, A.
    Mittal, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S688 - S688
  • [27] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Graf, Josephine
    Pape, Ulrich-Frank
    Jann, Henning
    Denecke, Timm
    Arsenic, Ruza
    Brenner, Winfried
    Pavel, Marianne
    Prasad, Vikas
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) : 881 - 894
  • [28] Establishing a Lu-177 Dotatate Therapy Program
    Snyder, W.
    Harpool, K.
    Swanson, J. W.
    Schantz, P.
    Phan, A.
    Dick, J. S.
    Cavanaugh, S. X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E499 - E500
  • [29] Size matters: A saga of Lu-177 yield
    Vyas, Madhusudan
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [30] Ac-225/Lu-177 Radiotheranostics
    Zhang, Jingjing
    CANCER SCIENCE, 2025, 116 : 178 - 178